Cargando…
Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node
BACKGROUND AND PURPOSE: The optimal treatment modality for clinically positive lateral pelvic lymph node (LPLN) from locally advanced rectal cancer (LARC) is unknown. Thus, we aimed to analyze the optimal radiotherapy dose for clinically positive LPLN from LARC. MATERIALS AND METHODS: We retrospecti...
Autores principales: | Li, Shuai, Zhang, Yangzi, Yu, Yang, Zhu, Xianggao, Geng, Jianhao, Teng, Huajing, Wang, Zhilong, Sun, Tingting, Wang, Lin, Wang, Hongzhi, Li, Yongheng, Wu, Aiwen, Cai, Yong, Wang, Weihu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937798/ https://www.ncbi.nlm.nih.gov/pubmed/33692945 http://dx.doi.org/10.3389/fonc.2020.627572 |
Ejemplares similares
-
Effect of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) and Non-Operative Strategy on Outcomes of Distal Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node
por: Li, Shuai, et al.
Publicado: (2021) -
Corrigendum: Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node
por: Li, Shuai, et al.
Publicado: (2021) -
Hyperfractionation versus Conventional Fractionation of Preoperative Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: A Propensity Score Matching Study
por: Shi, Chen, et al.
Publicado: (2022) -
Dentate line invasion as a predictive factor of poor distant relapse-free survival in locally advanced lower rectal cancer with anal sphincter involvement
por: Song, Maxiaowei, et al.
Publicado: (2022) -
One to Two Cycles of Consolidation Chemotherapy With Capecitabine After Neoadjuvant Chemoradiotherapy Does Not Benefit Low-Risk Patients With Locally Advanced Middle-Low Rectal Cancer
por: Sheng, Xueqing, et al.
Publicado: (2021)